Open Label Extension of the Phase 3 Study NEURO-TTR to Assess the Long-term Efficacy and Safety of Inotersen in Patients With Hereditary Transthyretin Amyloidosis (P1.324)
Thomas H. Brannagan(Columbia University), Morie A. Gertz(Medical University of South Carolina), Stephen B. Heitner(Brigham and Women's Hospital), Giuseppe Vita(University of Messina), Peter D. Gorevic(Université Paris-Sud), John L. Berk(Boston University), Hartmut Schmidt(Université Paris-Sud), Jesse Kwoh(Ionis Pharmaceuticals (United States)), Márcia Waddington‐Cruz(Université Paris-Sud), Annabel K. Wang(Université Paris-Sud), Brenda F. Baker(Ionis Pharmaceuticals (United States)), Josep M. Campistol(Universitat de Barcelona), Violaine Planté‐Bordeneuve(Université Paris-Est Créteil), Brett P. Monia(Ionis Pharmaceuticals (United States)), Fábio Barroso(Université Paris-Sud), Carol Whelan(The Royal Free Hospital), Isabel Conceição(Université Paris-Sud), Brian Drachman(Penn Presbyterian Medical Center), Steven G. Hughes(Ionis Pharmaceuticals (United States)), Michael Polydefkis(Université Paris-Sud), Josep Gámez(Université Paris-Sud), Giampaolo Merlini(University of Pavia), Morton Scheinberg(Université Paris-Sud), David Adams(Mount Sinai Health System), Teresa Coelho(Universidade do Porto), Elizabeth J. Ackermann(Université Paris-Sud), P. James B. Dyck(Mayo Clinic), Merrill D. Benson(Indiana University School of Medicine), Bradley McEvoy(Université Paris-Sud)
Cited by 2
Related Papers
Transcatheter Aortic-Valve Replacement with a Self-Expanding Valve in Low-Risk Patients
|New England Journal of Medicine|2019|3.6k
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|2.9k
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
|New England Journal of Medicine|2018|2.8k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting
|Cell Metabolism|2006|2.1k